CompletedNot applicableNCT00867659

The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors

Studying Ovarian hyperstimulation syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Virginia Center for Reproductive Medicine
Principal Investigator: Fady I Sharara, M.D
Virginia Center for Reproductive Medicine
Intervention: Cetrotide acetate(drug)
Enrollment: 20 target
Eligibility: 19-32 years · FEMALE
Timeline: 2009 – 2011

Study locations (1)

Virginia Center for Reproductive Medicine, Reston, Virginia, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00867659 on ClinicalTrials.gov

Other trials for Ovarian hyperstimulation syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT07043322
Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome
Tanta University

See all trials for Ovarian hyperstimulation syndrome →

← Back to all trials